Esmaeili Aryan, Hagedorn Hildi J, Garcia Carla C, Bangerter Ann, Gustavson Allison M, Kenny Marie E, Miller Wendy, Ackland Princess E, Clothier Barbara A, Noorbaloochi Siamak, Gordon Adam J, Bounthavong Mark
Health Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Center for Care Delivery & Outcomes Research, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA.
Subst Use Addctn J. 2025 Oct;46(4):901-912. doi: 10.1177/29767342251336035. Epub 2025 Apr 28.
To address the opioid use disorder (OUD) public health crisis, the ADvancing Pharmacological Treatments for OUD (ADaPT-OUD) external facilitation randomized trial was conducted in 8 intervention and 27 matched control low-performing Veterans Health Administration (VHA) facilities to increase the prescribing of medications for OUD (MOUD). Facilities were considered low-performers if they were in the bottom quartile of the facility ratio of Veterans with OUD who received MOUD. The objective of this analysis was to evaluate the healthcare expenditures of Veterans with OUD who received care in ADaPT-OUD intervention facilities compared to those receiving care in matched control facilities.
Difference-in-differences (DID) design was used to compare the overall, outpatient, and inpatient expenditures (extracted from the VHA data warehouse) of Veterans diagnosed with OUD or receiving MOUD between the 2 groups 12 months before and after the intervention.
A total of 7348 Veterans with a diagnosis of OUD or prescribed MOUD on at least 1 encounter 12 months after ADaPT-OUD intervention at all sites (92.39% male and 83.26% white) were included for analysis. ADaPT-OUD intervention did not have a substantial impact on overall healthcare costs. However, we reported 4% fewer total encounters in the intervention sites (DID, 95% confidence intervals [CI]: 0.96 [0.92-1.00]) compared to the control sites, driven by a decline in non-VA services. Notably, the outpatient psychiatric-related costs were $391 (95% CI: $49-$733) higher per Veteran within the year after the intervention sites received external facilitation compared to control sites.
Veterans at intervention sites with an OUD history had higher outpatient psychiatric-related costs, which could be explained by increased access to optimal mental health services at VHA. Improving access to OUD treatment at VA may lead to more coordinated and comprehensive treatment of both OUD and other associated mental health and physical comorbidities.
为应对阿片类药物使用障碍(OUD)公共卫生危机,开展了阿片类药物使用障碍推进药物治疗(ADaPT - OUD)外部促进随机试验,该试验在8个干预点和27个匹配的对照低绩效退伍军人健康管理局(VHA)设施中进行,以增加用于治疗OUD的药物(MOUD)的处方量。如果设施中接受MOUD治疗的患有OUD的退伍军人的设施比率处于底部四分位数,则该设施被视为低绩效设施。本分析的目的是评估在ADaPT - OUD干预设施接受治疗的患有OUD的退伍军人与在匹配的对照设施接受治疗的退伍军人的医疗保健支出。
采用差异中的差异(DID)设计,比较干预前后12个月两组中被诊断为OUD或接受MOUD治疗的退伍军人的总体、门诊和住院支出(从VHA数据仓库中提取)。
在所有地点,共有7348名退伍军人在ADaPT - OUD干预后12个月内至少有1次被诊断为OUD或开具了MOUD处方(92.39%为男性,83.26%为白人)纳入分析。ADaPT - OUD干预对总体医疗保健成本没有重大影响。然而,与对照地点相比,我们报告干预地点的总就诊次数减少了4%(DID,95%置信区间[CI]:0.96[0.92 - 1.00]),这是由非VA服务的减少所驱动。值得注意的是,在干预地点接受外部促进后的一年内,每位退伍军人的门诊精神科相关费用比对照地点高391美元(95%CI:49 - 733美元)。
有OUD病史的干预地点的退伍军人门诊精神科相关费用较高,这可能是由于在VHA获得了更多的最佳心理健康服务。改善在VA获得OUD治疗的机会可能会导致对OUD以及其他相关心理健康和身体合并症进行更协调和全面的治疗。